Faeth Therapeutics, Inc. (FTH)
| Market Cap | 835.68M +8,664.2% |
| Revenue (ttm) | n/a |
| Net Income | -195.53M |
| EPS | -82.46 |
| Shares Out | 25.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365,040 |
| Open | 29.95 |
| Previous Close | 28.55 |
| Day's Range | 28.73 - 33.20 |
| 52-Week Range | 7.21 - 37.90 |
| Beta | -0.31 |
| Analysts | Strong Buy |
| Price Target | 54.50 (+68.52%) |
| Earnings Date | Aug 4, 2026 |
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for FTH stock is "Strong Buy." The 12-month stock price target is $54.5, which is an increase of 68.52% from the latest price.
News
Faeth Therapeutics appoints Tiwari, Biegler as Senior Vice Presidents
Faeth Therapeutics (FTH) announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepa...
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice...
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an ag...
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, w...
Faeth Therapeutics management to meet with BTIG
Meeting to be held in Baltimore/Washington, DC on August 10 hosted by BTIG.
Faeth Therapeutics initiated with a Buy at JonesResearch
JonesResearch analyst Boris Peaker initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $55 price target The firm believes the company’s lead asset, Piktor, is potentially a best-in-cl...
Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year
“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics (FTH),” said Anand Parikh, Chief Executive Officer. “With the concurrent $200 million PI...
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, t...
Faeth Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $56 price target The firm’s thesis centers on PIKTOR’s potential as an oral PI3Kalpha/mTOR inhibitor offering...
Faeth Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $60 price target Revtorpyk’s approval in PIK3CA-WT HR+/HER2- breast cancer in July supports PIKTOR’s probabilit...
Faeth Therapeutics initiated with an Outperform at Citizens
Citizens initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $51 price target The company is focused on targeted therapies in oncology, the analyst tells investors in a…
Faeth Therapeutics, Inc trading resumes
15:41 EDT Faeth Therapeutics (FTH), Inc trading resumes
Faeth Therapeutics, Inc trading halted, volatility trading pause
15:31 EDT Faeth Therapeutics (FTH), Inc trading halted, volatility trading pause
Faeth Therapeutics initiated with an Outperform at Baird
Baird analyst Jack Allen initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $57 price target Faeth is built around Piktor, an oral, multi-node approach to inhibiting the…
Faeth Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $60 price target The firm has conviction on Faeth’s clinical-stage oncology pipeline centered on multi-node inhibit...
Faeth Therapeutics files automatic mixed securities shelf
16:03 EDT Faeth Therapeutics (FTH) files automatic mixed securities shelf
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company's common sto...
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employ...
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of...
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Pha...
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16...
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth...
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-nod...
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immun...
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics f...